表观遗传编辑和表观药物:一种组合策略,同时针对KDM4作为一种新型抗癌方法
Federica Sarno1,2, Jim J Jacob1, Roos E Eilers1
1Epigenetic Editing Research Group, Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.
Clinical epigenetics
|June 19, 2025
概括
将表观遗传编辑与表观药物结合起来,可以提供一种协同作用的抗癌策略. 这种方法抑制KDM4基因表达和蛋白质活性,降低毒性并增强对各种癌症的治疗效果.
科学领域:
- 表观遗传学和癌症治疗方法
- 基因调控和向治疗方法
背景情况:
- KDM4脱甲基酶 (KDM4-A/B/C) 在癌症中过度表达,使其成为治疗点.
- 现有的KDM4抑制剂 (epi药物) 面临着特异性和剂量限制性毒性方面的挑战.
- 表观遗传编辑 (epi-editing) 提供了一种精确的方法,通过表观遗传修饰来调节基因表达.
研究的目的:
- 研究将KDM4的epi编辑与epi药物治疗相结合的协同抗癌效应.
- 探索是否可以防止药物诱导KDM4基因表达的升调.
- 建立一种新的治疗策略,将epi药物和epi编辑结合起来,以改善癌症治疗.
主要方法:
- 利用CRISPRoff进行针对KDM4基因的表观遗传抑制.
- 使用泛KDM4抑制剂 (QC6352,JIB-04) 阻止KDM4蛋白活性.
- 验证了KDM4A下调和评估了各种癌细胞系中的抗癌作用 (MCF7,HCT116).
主要成果:
- 经编辑成功降低KDM4A的调节,抑制乳腺癌和结肠癌模型中的癌细胞生长.
- KDM4 抑制剂增加了 KDM4 基因表达,这种效应被并发的 epi 编辑阻止或抑制.
- 与单一治疗相比,结合后期编辑和后期药物治疗表明,与单一治疗相比,加强了癌细胞生长的抑制.
结论:
- 将epi编辑与epi药物结合起来,为癌症治疗提供了一种协同的方法.
- 这种双重目标策略可以减轻药物毒性,并通过抑制补偿基因上调来防止耐药性.
- 开发的治疗策略有望提高抗癌疗效和减少副作用.
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle
7.0K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Epigenetic Regulation
3.1K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.1K
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K


